
Robert Allison Franklin , MD
Assistant Professor of Clinical
University of Cincinnati Medical Center
234 Goodman St
234 Goodman St
Cincinnati, Ohio 45219
Phone 513-585-8222
Email franklro@ucmail.uc.edu
Education
Bachelor of Arts: University of Georgia Atlanta, GA, 2008 (Philosophy, English Literature)
MD: University of Tennessee Health Science Center College of Medicine Memphis, TN, 2015 (Medicine)
Residency: University of Cincinnati Medical Center Cincinnati, Ohio, 2018 (Internal Medicine)
Certifications
American Board of Internal Medicine (Certification Date: 08-24-2018 )
American Board of Internal Medicine (Hematology) (Certification Date: 11-30-2022 )
American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-29-2022 )
Clinical Interests
Lung Cancer
Thoracic Cancer
Medical Oncology
Oncology
Bladder Cancer
Kidney Cancer
Penile Cancer
Prostate Cancer
Testicular Cancer
Hematology and Oncology
Specialities
Internal Medicine
Hematology
Medical Oncology
Research Support
Grant: #D9723C00001 Investigators:Franklin, Robert 04-08-2024 -04-08-2027 AstraZeneca Pharmaceuticals LP A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration Role:PI 0.00 Hold Level:Industry
Investigators:Franklin, Robert 04-29-2024 -05-29-2024 Myovant Sciences Relugolix Versus Leuprolide in Patients with PRostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV) Role:PI 0.00 Hold Level:Industry
Investigators:Franklin, Robert 11-15-2024 -11-15-2027 ICON Clinical Research, LLC A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma Role:PI 760375.95 Hold Level:Industry
Grant: #HCRN-GU20-436 Investigators:Franklin, Robert 12-18-2024 -12-18-2027 Hoosier Cancer Research Network, Inc. HCRN-GU20-436: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alteration Role:PI 85922.50 Hold Level:Industry
Contact Information
Academic - University of Cincinnati Medical Center
234 Goodman St
CincinnatiĀ
Ohio, 45219
Phone: 513-585-8222
franklro@ucmail.uc.edu